Emanuela Salvatorelli

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 39 publications

Bruton tyrosine kinase inhibitors and cardiovascular adverse events.

Bruton tyrosine kinase inhibitors and cardiovascular adverse events.

Journal: British journal of pharmacology

Published: March 28, 2026

Adjudication of Adverse Cardiovascular Events in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib: Deaths in GLOW or Blowing in the Wind?

Adjudication of Adverse Cardiovascular Events in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib: Deaths in GLOW or Blowing in the Wind?

Journal: European cardiology

Published: May 14, 2025

Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogeny.

Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogeny.

Journal: British journal of pharmacology

Published: November 06, 2024

Anthracyclines, Diastolic Dysfunction and the road to Heart Failure in Cancer survivors: An untold story.

Anthracyclines, Diastolic Dysfunction and the road to Heart Failure in Cancer survivors: An untold story.

Journal: Progress in cardiovascular diseases

Published: July 14, 2024

Humans and Rodents: The Case of hOAT4 and mOat5.

Humans and Rodents: The Case of hOAT4 and mOat5.

Journal: The Journal of pharmacology and experimental therapeutics

Published: May 16, 2024

Anthracyclines and Cardiotoxicity: Is CARP a Forgotten Biomarker?

Anthracyclines and Cardiotoxicity: Is CARP a Forgotten Biomarker?

Journal: Journal of cardiovascular pharmacology

Published: October 04, 2023

Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study.

Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study.

Journal: Clinical and translational science

Published: June 09, 2023

New Targeted Drugs for Acute Myeloid Leukemia and Antifungals: Pharmacokinetic Challenges and Opportunities.

New Targeted Drugs for Acute Myeloid Leukemia and Antifungals: Pharmacokinetic Challenges and Opportunities.

Journal: Chemotherapy

Published: January 27, 2023

Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology.

Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology.

Journal: Advances in pharmacology (San Diego, Calif.)

Published: June 06, 2022

From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational Approach.

From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational Approach.

Journal: JACC. CardioOncology

Published: May 02, 2022

Cardiac Anthracycline Accumulation and B-Type Natriuretic Peptide to Define Risk and Predictors of Cancer Treatment-Related Early Diastolic Dysfunction.

Cardiac Anthracycline Accumulation and B-Type Natriuretic Peptide to Define Risk and Predictors of Cancer Treatment-Related Early Diastolic Dysfunction.

Journal: The Journal of pharmacology and experimental therapeutics

Published: January 10, 2022

Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life.

Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life.

Journal: Chemotherapy

Published: November 24, 2020

Showing 1-12 of 39

Last Updated: 09/26/2026